TW202321216A - 晶形 - Google Patents

晶形 Download PDF

Info

Publication number
TW202321216A
TW202321216A TW111128732A TW111128732A TW202321216A TW 202321216 A TW202321216 A TW 202321216A TW 111128732 A TW111128732 A TW 111128732A TW 111128732 A TW111128732 A TW 111128732A TW 202321216 A TW202321216 A TW 202321216A
Authority
TW
Taiwan
Prior art keywords
piperidin
dimethyl
oxo
piperidine
oxindolin
Prior art date
Application number
TW111128732A
Other languages
English (en)
Chinese (zh)
Inventor
青山英幸
沼田豊治
須藤正樹
岩田康弘
Original Assignee
日商拉夸里亞創藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商拉夸里亞創藥股份有限公司 filed Critical 日商拉夸里亞創藥股份有限公司
Publication of TW202321216A publication Critical patent/TW202321216A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW111128732A 2021-07-30 2022-08-01 晶形 TW202321216A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163227692P 2021-07-30 2021-07-30
US63/227,692 2021-07-30

Publications (1)

Publication Number Publication Date
TW202321216A true TW202321216A (zh) 2023-06-01

Family

ID=85087024

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111128732A TW202321216A (zh) 2021-07-30 2022-08-01 晶形

Country Status (10)

Country Link
US (1) US12552776B2 (https=)
EP (1) EP4377309A4 (https=)
JP (1) JP7765130B2 (https=)
KR (1) KR20240042400A (https=)
CN (1) CN117616022A (https=)
BR (1) BR112023025271A2 (https=)
CA (1) CA3223173A1 (https=)
MX (1) MX2024000903A (https=)
TW (1) TW202321216A (https=)
WO (1) WO2023008585A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600510C (en) 2005-03-11 2010-11-02 Pfizer Inc. Crystal forms of an imidazole derivative
KR101575703B1 (ko) * 2009-02-27 2015-12-10 라퀄리아 파마 인코포레이티드 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체
WO2012157288A1 (en) 2011-05-18 2012-11-22 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CA2944982C (en) 2014-05-20 2022-06-07 Raqualia Pharma Inc. Benzisoxazole derivative salt

Also Published As

Publication number Publication date
BR112023025271A2 (pt) 2024-02-27
EP4377309A1 (en) 2024-06-05
EP4377309A4 (en) 2025-06-25
JP7765130B2 (ja) 2025-11-06
JP2024526952A (ja) 2024-07-19
CN117616022A (zh) 2024-02-27
US20240351998A1 (en) 2024-10-24
KR20240042400A (ko) 2024-04-02
US12552776B2 (en) 2026-02-17
CA3223173A1 (en) 2023-02-02
WO2023008585A1 (en) 2023-02-02
MX2024000903A (es) 2024-02-06

Similar Documents

Publication Publication Date Title
CN103702995B (zh) 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
CN104837836B (zh) 多晶型物
RU2679619C2 (ru) Солевое производное бензизоксазола
JP7765130B2 (ja) 結晶形
HK40101847A (zh) 晶形
TW202513058A (zh) 氮螺環衍生物鹽
HK1195066B (en) Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
HK1231483B (en) Benzisoxazole derivative salt
HK1209122B (en) Polymorphs of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid as 5-hydroxytryptamine-4 (5-ht4) receptor agonists for the treatment of gastrointestinal diseases